Pfizer Release - Search News

Pfizer, Metsera and Novo Nordisk

Novo Nordisk Not Planning Increased Proposal Offer After Metsera Enters $10 Billion Amended Merger Agreement with Pfizer

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an amended acquisition proposal to Metsera for $62.20 per share, a total value of $7.2 billion. Shortly after receiving the amended proposal, Metsera’s board of directors suggested to stockholders to approved Pfizer’s acquisition. 3

· 5h

Metsera: Why Pfizer And Novo Nordisk Fought Hard Over This Obesity Drug Developer

Zacks Investment Research on MSN · 1d

Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B

Pfizer shows hardball mettle needed to win in 2025 M&A

Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk ...

8don MSN

Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute

Pfizer (PFE) is set to report its Q3 earnings on Tuesday, November 4, before the market opens. Wall Street expects earnings ...

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results